Exercise Group for Parkinson's (NCT07618728)
Improve walking stability with exercise
- Trial ID
- NCT07618728
- Official Title
- Feasibility and Preliminary Effectiveness of an Individualised Multimodal Group-Based Exercise Programme for People With Parkinson's Disease: A Non-Randomized Feasibility Study
- Goal
- Improve walking stability with exercise
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universidad Rey Juan Carlos
- Study Type
- INTERVENTIONAL
- Enrollment
- 64 participants
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Exercise Group
Summary For Families
A team is testing whether a tailored, multimodal group exercise program can be safely delivered and help improve balance, strength, walking and daily function in people with early to mid-stage Parkinson's. Participants do small, supervised group classes with individualized strength, aerobic, balance and flexibility exercises, designed to boost muscle power, endurance and motor control and to complement medications like levodopa rather than replace them. Adults 18 and older with idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3 who can follow instructions are eligible, while people with other neurological or serious medical conditions, significant cognitive impairment (MoCA < 21), recent hospitalization or recent structured exercise are excluded. About 64 people will enroll, with control participants matched to the exercise group by age, sex and disease stage in a sequential recruitment plan to check feasibility and early benefits.
Locations
- Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Exercise Group. A team is testing whether a tailored, multimodal group exercise program can be safely delivered and help improve balance, strength, walking and daily function in people with early to mid-stage Parkinson's. Participants do small, supervised group classes with individualized strength, aerobic, balance and flexibility exercises, designed to boost muscle power, endurance and motor control and to complement medications like levodopa rather than replace them. Adults 18 and older with idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3 who can follow instructions are eligible, while people with other neurological or serious medical conditions, significant cognitive impairment (MoCA < 21), recent hospitalization or recent structured exercise are excluded. About 64 people will enroll, with control participants matched to the exercise group by age, sex and disease stage in a sequential recruitment plan to check feasibility and early benefits.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 9 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This trial has a group that receives no study treatment (you would continue your usual care) alongside the treatment group. Because assignment is random, you have about a 1 in 2 chance (roughly 50%) of being in the no-treatment group, assuming the groups are filled equally. Ask the coordinator to confirm the exact assignment ratio.
- How many visits does this trial involve?
- The intervention involves two weekly supervised face-to-face sessions for 12 weeks (plus one weekly home-based session).